| 杨 冬,辛 勇,陈 辰,卢其香,孙立柱.血清TAP、PDCD-5、TNF-α与晚期非小细胞肺癌患者抗PD-1治疗疗效的关系分析[J].现代生物医学进展英文版,2022,(14):2737-2742. |
| 血清TAP、PDCD-5、TNF-α与晚期非小细胞肺癌患者抗PD-1治疗疗效的关系分析 |
| Analysis of the Relationship between Serum TAP, PDCD-5, TNF-α and Anti-PD-1 Therapy in Patients with Advanced Non-Small Cell Lung Cancer |
| Received:January 20, 2022 Revised:February 16, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.14.028 |
| 中文关键词: 晚期 非小细胞肺癌 TAP PDCD-5 TNF-α 抗PD-1治疗 |
| 英文关键词: Advanced Non-small cell lung cancer TAP PDCD-5 TNF-α Anti-PD-1 therapy |
| 基金项目:江苏省人社厅第十四批"六大人才高峰"高层次人才项目（WSN-121） |
|
| Hits: 667 |
| Download times: 338 |
| 中文摘要: |
| 摘要 目的：探讨血清肿瘤异常蛋白（TAP）、程序化细胞死亡分子5（PDCD-5）、肿瘤坏死因子-α（TNF-α）与晚期非小细胞肺癌（NSCLC）患者抗程序性死亡受体1（PD-1）治疗疗效的关系。方法：选取2018年3月至2021年3月徐州医科大学附属沭阳医院肿瘤科收治的87例晚期NSCLC患者，均行抗PD-1治疗，根据治疗疗效分为疾病控制组（67例）和疾病进展组（20例）。检测对比两组患者治疗前后血清TAP、PDCD-5、TNF-α水平，收集临床资料，采用多因素Logistic回归分析NSCLC患者抗PD-1治疗疗效的影响因素，绘制受试者工作特征（ROC）曲线分析TAP、PDCD-5、TNF-α水平对NSCLC患者抗PD-1治疗疗效的评估价值。结果：疾病控制组患者治疗后血清TAP水平降低，PDCD-5、TNF-α水平升高（P＜0.05）；疾病进展组患者治疗前后血清TAP、PDCD-5、TNF-α水平比较无统计学差异（P＞0.05）；治疗后，疾病控制组患者血清TAP水平低于疾病进展组患者，PDCD-5、TNF-α水平高于疾病进展组患者（P＜0.05）。多因素Logistic回归分析结果显示：治疗前TAP水平以及远处转移是 NSCLC患者抗PD-1治疗疗效的危险因素（P＜0.05），治疗前PDCD-5、TNF-α水平是保护因素（P＜0.05）。ROC曲线分析结果显示：联合检测治疗前血清TAP、PDCD-5、TNF-α评估NSCLC患者抗PD-1治疗疗效的曲线下面积（AUC）为0.892，高于上述三项指标单独检测的0.649、0.647、0.787。结论：晚期NSCLC患者抗PD-1治疗前血清TAP、PDCD-5、TNF-α与治疗疗效相关，可用于辅助评估抗PD-1疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum tumor abnormal protein (TAP), programmed cell death molecule 5 (PDCD-5), tumor necrosis factor-α (TNF-α) and anti-programmed death receptor 1 (PD-1) in patients with advanced non-small cell lung cancer (NSCLC). Methods: 87 patients with advanced NSCLC who were admitted to Department of Oncology,Shuyang Hospital Affiliated to Xuzhou Medical University from March 2018 to March 2021 were selected. All patients were treated with anti-PD-1, and they were divided into disease control group (67 cases) and disease progression group (20 cases) according to treatment efficacy. Serum TAP, PDCD-5 and TNF-α levels were detected and compared between two groups before and after treatment, and clinical data were collected. Multiple Logistic regression was used to analyze the influencing factors of anti-PD-1 therapy efficacy in patients with NSCLC. Receiver operating characteristic (ROC) curve was drawn to analyze the evaluation value of TAP, PDCD-5 and TNF-α levels for anti-PD-1 therapy in patients with NSCLC. Results: After treatment, the serum TAP level of patients in disease control group decreased, the PDCD-5 and TNF-α levels increased (P<0.05). There was no significant differences in serum TAP, PDCD-5 and TNF-α levels in patients with disease progression group before and after treatment (P>0.05). After treatment, the serum TAP level of patients in the disease control group was lower than that in the disease progression group, while the PDCD-5 and TNF-α levels were higher than those in the disease progression group (P<0.05). Logistic regression analysis showed that the of serum TAP levels and distant visceral metastasis were risk factors for anti-PD-1 treatment efficacy in NSCLC patients (P<0.05), and PDCD-5 and TNF-α were protective factors before treatment (P<0.05). ROC curve analysis showed that the area under the curve (AUC) of the combined detection of TAP, PDCD-5 and TNF-α in serum for evaluating the efficacy of anti-PD-1 treatment in patients with NSCLC was 0.892, which was higher than 0.649, 0.647 and 0.787 of the above three indicators alone. Conclusion: The serum TAP, PDCD-5 and TNF-α before treatment of patients with advanced NSCLC before and after anti-PD-1 therapy are correlated with therapeutic efficacy, which could be used as indicators for evaluation of anti-PD-1 efficacy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
